Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity-Modulated Radiation Therapy

IF 6.5 1区 医学 Q1 ONCOLOGY International Journal of Radiation Oncology Biology Physics Pub Date : 2025-03-15 Epub Date: 2024-11-12 DOI:10.1016/j.ijrobp.2024.10.007
Diana A. Roth O'Brien MD, MPH , Vasilis C. Hristidis MD , Zakaria Chakrani MD , Patrick McCann MSc , Antonio Damato PhD , Vonetta Williams MD, PhD , Nicolas Cote MSc , Marsha Reyngold MD, PhD , Roni Rosen MD , Louise Connell MD , Emmanouil Pappou MD, MPH , Carla Hajj MD , Philip B. Paty MD , Natally Horvat MD , Jennifer S. Golia Pernicka MD , Megan Fiasconaro MS , Jinru Shia MD , Jeanine Lisanti BA , Abraham J. Wu MD , Marc J. Gollub MD , Paul B. Romesser MD
{"title":"Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity-Modulated Radiation Therapy","authors":"Diana A. Roth O'Brien MD, MPH ,&nbsp;Vasilis C. Hristidis MD ,&nbsp;Zakaria Chakrani MD ,&nbsp;Patrick McCann MSc ,&nbsp;Antonio Damato PhD ,&nbsp;Vonetta Williams MD, PhD ,&nbsp;Nicolas Cote MSc ,&nbsp;Marsha Reyngold MD, PhD ,&nbsp;Roni Rosen MD ,&nbsp;Louise Connell MD ,&nbsp;Emmanouil Pappou MD, MPH ,&nbsp;Carla Hajj MD ,&nbsp;Philip B. Paty MD ,&nbsp;Natally Horvat MD ,&nbsp;Jennifer S. Golia Pernicka MD ,&nbsp;Megan Fiasconaro MS ,&nbsp;Jinru Shia MD ,&nbsp;Jeanine Lisanti BA ,&nbsp;Abraham J. Wu MD ,&nbsp;Marc J. Gollub MD ,&nbsp;Paul B. Romesser MD","doi":"10.1016/j.ijrobp.2024.10.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Patterns of failure and salvage therapy options for patients with anal squamous cell carcinoma (ASCC) who recur after definitive-intent intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy are not well described.</div></div><div><h3>Methods and Materials</h3><div>We identified consecutive patients with ASCC treated with definitive-intent IMRT between July 2005 and December 2019. Relevant patient and tumor parameters, disease outcomes (locoregional failure [LRF], distant failure, progression-free survival, colostomy-free survival, and overall survival [OS]), patterns of failure, and salvage therapies were collected. Failures were analyzed using competing risk methods, whereas survival endpoints were estimated using the Kaplan-Meier method. Univariate and multivariate analyses were performed. Landmark analyses were conducted by considering whether patients had LRF within 12 months of completing IMRT.</div></div><div><h3>Results</h3><div>A total of 375 patients were identified with a median follow-up of 6 years. Stage breakdown was 15%, 23%, and 62% for the American Joint Committee on Cancer stages 0 to I, II, and III, respectively. Six-year rates of LRF, distant failure, progression-free survival, colostomy-free survival, and OS were 12%, 13%, 73%, 76%, and 80%, respectively. Disease recurred in 74 patients. Among the 45 patients with LRF, 39 (87%) failed within the anorectum, with 25 anal canal, 6 anal margin, and 8 rectal recurrences. Only 4 (9%) patients had isolated nodal failure. Patients experiencing LRF had worse 6-year OS than patients without LRF (44% vs 86%, <em>P</em> &lt; .0001). Approximately 30% of patients who underwent salvage therapy were alive to 10 years after recurrence, compared with none of the patients who were managed with chemotherapy alone or the best supportive care.</div></div><div><h3>Conclusions</h3><div>This large ASCC cohort managed with definitive-intent IMRT demonstrated excellent rates of locoregional control and survival. Isolated regional nodal failures were uncommon, whereas the majority of LRFs occurred within the anorectum, despite dose escalation by tumor stage. We observed poor outcomes for patients experiencing locoregional disease recurrence, even after aggressive salvage treatment.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 4","pages":"Pages 951-962"},"PeriodicalIF":6.5000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624034709","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Patterns of failure and salvage therapy options for patients with anal squamous cell carcinoma (ASCC) who recur after definitive-intent intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy are not well described.

Methods and Materials

We identified consecutive patients with ASCC treated with definitive-intent IMRT between July 2005 and December 2019. Relevant patient and tumor parameters, disease outcomes (locoregional failure [LRF], distant failure, progression-free survival, colostomy-free survival, and overall survival [OS]), patterns of failure, and salvage therapies were collected. Failures were analyzed using competing risk methods, whereas survival endpoints were estimated using the Kaplan-Meier method. Univariate and multivariate analyses were performed. Landmark analyses were conducted by considering whether patients had LRF within 12 months of completing IMRT.

Results

A total of 375 patients were identified with a median follow-up of 6 years. Stage breakdown was 15%, 23%, and 62% for the American Joint Committee on Cancer stages 0 to I, II, and III, respectively. Six-year rates of LRF, distant failure, progression-free survival, colostomy-free survival, and OS were 12%, 13%, 73%, 76%, and 80%, respectively. Disease recurred in 74 patients. Among the 45 patients with LRF, 39 (87%) failed within the anorectum, with 25 anal canal, 6 anal margin, and 8 rectal recurrences. Only 4 (9%) patients had isolated nodal failure. Patients experiencing LRF had worse 6-year OS than patients without LRF (44% vs 86%, P < .0001). Approximately 30% of patients who underwent salvage therapy were alive to 10 years after recurrence, compared with none of the patients who were managed with chemotherapy alone or the best supportive care.

Conclusions

This large ASCC cohort managed with definitive-intent IMRT demonstrated excellent rates of locoregional control and survival. Isolated regional nodal failures were uncommon, whereas the majority of LRFs occurred within the anorectum, despite dose escalation by tumor stage. We observed poor outcomes for patients experiencing locoregional disease recurrence, even after aggressive salvage treatment.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
大量现代肛门鳞状细胞癌患者接受明确意向性 IMRT 治疗后的临床疗效、失败模式和挽救疗法。
目的:肛门鳞状细胞癌(ASCC)患者在接受明确意图调强放疗(IMRT)并同时接受化疗后复发的失败模式和挽救治疗方案尚未得到很好的描述:我们确定了2005年7月至2019年12月期间接受明确意图IMRT治疗的连续ASCC患者。收集了相关的患者和肿瘤参数、疾病结局(局部失败(LRF)、远处失败(DF)、无进展生存期(PFS)、无结肠造口生存期(CFS)和总生存期(OS))、失败模式和挽救疗法。采用竞争风险法分析失败情况,采用卡普兰-梅耶法估算生存终点。进行了单变量和多变量分析。通过考虑患者是否在完成 IMRT 后 12 个月内出现 LRF,进行了标志性分析:结果:共发现 375 例患者,中位随访时间为 6 年。AJCC 0-I、II 和 III 期患者的分期率分别为 15%、23% 和 62%。6年的LRF、DF、PFS、CFS和OS率分别为12%、13%、73%、76%和80%。74名患者病情复发。在45例LRF患者中,39例(87%)在肛门直肠内复发,其中25例为肛管复发,6例为肛缘复发,8例为直肠复发。只有 4 例(9%)患者出现孤立的结节失败。出现 LRF 的患者的 6 年 OS 不如未出现 LRF 的患者(44% 对 86%,PC 结论:这一大型 ASCC 队列采用最终意图 IMRT 治疗,显示出极佳的局部控制率和生存率。孤立的区域性结节失败并不常见,而大多数 LRF 发生在肛门直肠内,尽管根据肿瘤分期进行了剂量升级。我们观察到,即使经过积极的挽救治疗,局部疾病复发患者的预后也很差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
期刊最新文献
The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer FLASH Radiation Therapy Using High-Energy X-Rays: Validation of the Flash Effect Triggered by a Compact Device Reduction of Bone Fracture After Radiation Therapy in Lower Extremity Soft Tissue Sarcoma After Implementing Bone Avoidance Objectives for Radiation Therapy Planning Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1